⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

March 1, 2024Cancer Discovery

A Highly Anticipated Selective Therapeutic Agent against CDK2: INX-315

Lotte P. Watts Sabrina L. Spencer

View at Publisher

Ask AI

Bookmark

Share

Abstract

Summary: In this issue, Dietrich, Trub, and colleagues describe and characterize a novel selective CDK2 inhibitor: INX-315. This agent shows promise in CCNE1-amplified cancers and in CDK4/6 inhibitor–resistant breast cancers. See related article by Dietrich et al., p. 446 (8).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Watts et al. (2024) studied this question.

synapsesocial.com/papers/68e76495b6db6435876da1fc https://doi.org/10.1158/2159-8290.cd-23-1537

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Data from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors2024
2Figure 1 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors2024
3Supplementary Figures 1-14 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors2024
4Supplementary Figures 1-14 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors2024
5Supplementary Figures 1-14 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors2025

More related papers

Supplementary Synthetic Methods from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors2025
Supplementary Synthetic Methods from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors2024
Supplementary Synthetic Methods from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors2024

More from Cancer Discovery

Shared-Antigen Cancer Vaccines Keep Falling ShortTue,
H3K4me1-Mediated Epigenomic Priming of Chemoresistant Tumor States in Ovarian CancerMon,